The global active pharmaceutical ingredients market was worth US$ 176.3 Billion in 2018. Active pharmaceutical ingredient (API), is the term that is used to refer to the biologically active component of a drug (e.g. tablet, capsule). A drug is usually composed of several components. The API represents the primary ingredient. Other ingredients are commonly known as “excipients. Sometimes a drug can contain several APIs and its effect on a patient depends on the dosage prescribed and can vary from person to person. In combination therapies, two or more than two active ingredients are used to treat different symptoms in different ways. Stringent quality control is a mandate when it comes to the manufacturing of drugs as the API represents the main component considered while making the prescription.
Pharmaceutical manufacturing occurs in two general steps. In the first step, manufacturers convert raw materials into APIs. The second step involves creating the final formulation by mixing APIs and excipients into tablets, capsules, solutions, etc. and finally packaging the drug for the end users. Manufacturers either sell APIs in the open market (also known as the merchant market) or use them as inputs to make their final formulations. The global API market is extremely competitive with a number of large and small manufacturers. Firms that engage in API manufacturing generally specialize and target their manufacturing based on a combination of the firms in-house skills and market opportunities. Catalyzed by lower costs, API manufacturing has gradually been shifting from the historical leaders in Western countries to manufacturers based in India and China.
The global demand of APIs is currently exhibiting strong growth. One of the major drivers of this market is the rising number of blockbuster patent expiries creating a significant opportunity for generic APIs. Moreover, there has been a strong demand for APIs for biologicals. The global market for biologicals is currently exhibiting strong growth catalyzed by their high potency and ability to treat diseases beyond the scope of small molecule drugs. This is creating a strong demand for APIs for branded biological drugs and their biosimilar versions. Other factors catalyzing the global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 247.2 Billion by 2024, exhibiting a CAGR of 5.8% during 2019-2024.
Market Summary:
Based on the drug type, the market has been segmented as innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients.
Based on the type of manufacturer, the market has been segmented as captive manufacturers and merchant API manufacturers.
Based on the type of synthesis, the market has been segmented as synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients.
Based on the therapeutic application, the market has been segmented as oncology, cardiovascular disease, diabetes, central nervous system and neurological disorders, endocrinology and others.
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The competitive landscape of the market has also been examined with some of the key players being Pfizer, Inc., Novartis International AG, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., ELI Lilly and Company, GlaxoSmithKline, Merck & Co., Inc. and Abbvie Inc.
Key Questions Answered in This Report:
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Active Pharmaceutical Ingredients Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Drug Type 5.4 Market Breakup by Type of Manufacturer 5.5 Market Breakup by Type of Synthesis 5.6 Market Breakup by Therapeutic Application 5.7 Market Breakup by Region 5.8 Market Forecast 5.9 SWOT Analysis 5.9.1 Overview 5.9.2 Strengths 5.9.3 Weaknesses 5.9.4 Opportunities 5.9.5 Threats 5.10 Value Chain Analysis 5.11 Porters Five Forces Analysis 5.11.1 Overview 5.11.2 Bargaining Power of Buyers 5.11.3 Bargaining Power of Suppliers 5.11.4 Degree of Competition 5.11.5 Threat of New Entrants 5.11.6 Threat of Substitutes 5.12 Price Analysis 5.12.1 Price Indicators 5.12.2 Price Structure 5.12.3 Margin Analysis 6 Market Breakup by Drug Type 6.1 Innovative Active Pharmaceutical Ingredients 6.2 Generic Active Pharmaceutical Ingredients 7 Market Breakup by Type of Manufacturer 7.1 Captive Manufacturers 7.2 Merchant API Manufacturers 7.2.1 Innovative Merchant API Manufacturers 7.2.2 Generic Merchant API Manufacturers 8 Market Breakup by Type of Synthesis 8.1 Synthetic Active Pharmaceutical Ingredients 8.1.1 Market Breakup by Type 8.1.1.1 Innovative Synthetic APIs 8.1.1.2 Generic Synthetic APIs 8.2 Biotech Active Pharmaceutical Ingredients 8.2.1 Market Breakup by Type 8.2.1.1 Innovative Biotech APIs 8.2.1.2 Biosimilars 8.2.2 Market Breakup By Product 8.2.2.1 Monoclonal Antibodies 8.2.2.2 Vaccines 8.2.2.3 Cytokines 8.2.2.4 Fusion Proteins 8.2.2.5 Therapeutic Enzymes 8.2.2.6 Blood Factors 8.2.3 Market Breakup By Expression System 8.2.3.1 Mammalian Expression Systems 8.2.3.2 Microbial Expression Systems 8.2.3.3 Yeast Expression Systems 8.2.3.4 Plant Expression Systems 8.2.3.5 Insect Expression Systems 9 Market Breakup by Therapeutic Application 9.1 Oncology 9.2 Cardiovascular Disease 9.3 Diabetes 9.4 Central Nervous System and Neurological Disorders 9.5 Endocrinology 9.6 Others 10 Market Breakup by Region 10.1 North America 10.2 Europe 10.3 Asia Pacific 10.4 Middle East and Africa 10.5 Latin America 11 Manufacturing Process 11.1 Product Overview 11.2 Raw Material Requirements 11.3 Manufacturing Process 11.4 Key Success and Risk Factors 12 Competitive Landscape 12.1 Market Structure 12.2 Key Players 12.3 Profiles of Key Players 12.3.1 Pfizer, Inc. 12.3.2 Novartis International AG 12.3.3 Sanofi 12.3.4 Boehringer Ingelheim 12.3.5 Bristol-Myers Squibb 12.3.6 Teva Pharmaceutical Industries Ltd. 12.3.7 ELI Lilly and Company 12.3.8 GlaxoSmithKline 12.3.9 Merck & Co., Inc. 12.3.10 Abbvie Inc. |
Market Breakup by Drug Type
Innovative Active Pharmaceutical Ingredients
Generic Active Pharmaceutical Ingredients
Market Breakup by Type of Manufacturer
Captive Manufacturers
Merchant API Manufacturers
Innovative Merchant API Manufacturers
Generic Merchant API Manufacturers
Market Breakup by Type of Synthesis
Synthetic Active Pharmaceutical Ingredients
Market Breakup by Type
Innovative Synthetic APIs
Generic Synthetic APIs
Biotech Active Pharmaceutical Ingredients
Market Breakup by Type
Innovative Biotech APIs
Biosimilars
Market Breakup By Product
Monoclonal Antibodies
Vaccines
Cytokines
Fusion Proteins
Therapeutic Enzymes
Blood Factors
Market Breakup By Expression System
Mammalian Expression Systems
Microbial Expression Systems
Yeast Expression Systems
Plant Expression Systems
Insect Expression Systems
Market Breakup by Therapeutic Application
Oncology
Cardiovascular Disease
Diabetes
Central Nervous System and Neurological Disorders
Endocrinology
Others
Market Breakup by Region
North America
Europe
Asia Pacific
Middle East and Africa
Latin America